• Volume • • Electronic publication date: 28/03/2024

A comparison of post-COVID vaccine myocarditis classification using the Brighton Collaboration criteria versus (United States) Centers for Disease Control criteria: an update

Kevin M Slater, Jim P Buttery, Nigel W Crawford, Daryl R Cheng

# Introduction

Myocarditis associated with coronavirus disease 2019 (COVID-19) vaccination is a known adverse event following immunisation (AEFI). The lack of a singular diagnostic marker or test for myocarditis, besides the now infrequently undertaken histological diagnosis from biopsy, means that a combination of criteria is often needed to confirm a diagnosis.

We have previously compared various international case definitions used to support accurate diagnosis and therefore standardise treatment and management of myocarditis.1 As more information about this important AEFI has come to light, some case definitions have been refined to provide greater sensitivity. Since our initial findings,2 the Brighton Collaboration (BC) Myocarditis/ Pericarditis working group have published updated diagnostic criteria.3 An important specific update is that a reported case with symptoms consistent with myocarditis, combined with abnormal cardiac medical resonance imaging (CMR), is now classified as a ‘probable’ case using the BC criteria – even in the absence of a raised troponin level. This therefore brings the BC definition for a Level 2 or ‘probable’ case in line with a ‘probable case’ using the United States Centers for Disease Control and Prevention (CDC) criteria (Table 1).4

Given these edits, this paper aims to refine our previous findings using updated diagnostic criteria, and to evaluate if there remain discrepancies in diagnosis and data reporting between the CDC (June 2021) and BC (June 2022) criteria.

# Methods

Between 1 February 2021 and 4 May 2022, Victoria’s vaccine safety surveillance system (Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC) received 460 reports of myocarditis temporally associated with COVID-19 vaccination.2 Every AEFI case was also reported to the Therapeutic Goods Administration (TGA), the body that aggregates national AEFI cases on a weekly basis.

The SAFEVIC group obtained information and findings for each case to allow for diagnostic certainty classification. Two authors used the updated case definition criteria to classify each case, with any discrepancies in classification verified by a third author. No external funding was received for this study.

# Results and discussion

Of 440 reported cases of myocarditis, 225 were classified as either ‘confirmed’ or ‘probable’ cases according to CDC or BC criteria (Table 1). There were no Level 3 or ‘possible’ cases as per BC criteria. Of the remaining cases, 37 were excluded due to a more likely alternative cause of myocarditis; 121 because they did not meet any criteria for a classification of myocarditis; and 57 because there was inadequate information to make a classification.

Even with the updated criteria, there was no change in classification level of any of the 225 cases. The BC criteria defined 79 cases (35%) as level 1 (definitive) and 146 (65%) as level 2 (probable). The CDC criteria defined 60 (27%) as confirmed, and 165 (73%) as probable. All 60 level 1 or confirmed CDC cases were also categorised as level 1 or definitive using the BC criteria. Of the 165 level 2 or probable CDC cases, 146 were BC probable and 19 were BC definitive. All 146 BC level 2 (probable) cases also met the criteria for CDC probable cases.

The authors believe the identical distribution, despite updated BC criteria, demonstrates that it was rare for myocarditis cases to have an isolated abnormal CMR without a corresponding elevated troponin in our cohort. This is most likely due to resource access, with troponin more widely available as a first line biomarker for all cases, whereas CMR was only used in a much smaller proportion.

The discrepancies between the two criteria were 19 cases classified as definitive by BC criteria but probable by CDC criteria. This discrepancy was due to all cases having echocardiogram abnormalities but without any CMR imaging; CDC-confirmed cases require positive CMR findings if there is no histopathology, while echocardiogram abnormalities and elevated troponin alone are sufficient to classify a case as BC definitive.

While CMR may be less accessible than echocardiography, it is often more sensitive in diagnosing myocarditis due to its identification of late gadolinium enhancement (LGE), which provides evidence of myocardial injury such as necrosis, oedema, and fibrosis.3 It remains paramount as an investigation contributing to diagnosis in both the CDC and updated BC criteria, particularly because of its effectiveness and non-invasive methodology. This is important as myocarditis AEFI is predominant in the adolescent and young adult cohort, where the alternative gold-standard cardiac biopsy is less frequently performed due to its invasive nature.

If CMR is not available, echocardiography can be useful for functional assessment of the heart. Transoesophageal echocardiography is considered gold-standard when transthoracic views are limited. In settings where CMR or echocardiography are both unavailable, the BC criteria may prove more sensitive in diagnosis of myocarditis. This is because it includes a Level 3 or ‘possible case’ definition, which relies on more easily accessible investigations such as a chest X-ray or an electrocardiogram (ECG). A corresponding possible case definition does not exist in the CDC criteria.

# Conclusion

Our findings continue to provide a valuable assessment of the utility of different criteria for myocarditis cases following COVID-19 vaccination. Local guidelines may consider recommending BC criteria where CMR or echocardiography is unavailable, as it demonstrates increased sensitivity for the diagnosis of myocarditis. The current study highlights the importance of refining criteria for AEFI based on evolving data, outcomes and availability of diagnostic tools.

Table 1: Comparison of diagnostic criteria for myocarditis

| Brighton Collaboration criteria | CDC criteriaa |
| --- | --- |
| **Level 1 (definitive)**Abnormal histopathologyORElevated troponin AND abnormal CMRbORElevated troponin AND abnormal echocardiography | **Level 1 (confirmed)**Symptoms consistent with myocarditis and at least one of:Abnormal histopathologyORElevated troponin AND abnormal CMR |
| **Level 2 (probable)**Symptoms consistent with myocarditis and at least one of:Abnormal CMRORElevated troponin or CKMBcORAbnormal ECGdORAbnormal echocardiography | **Level 2 (probable)**Symptoms consistent with myocarditis and at least one of:Abnormal CMRORAbnormal troponinORAbnormal ECGORAbnormal echocardiography |
| **Level 3 (possible case)**Symptoms consistent with myocarditisANDEnlarged heart on CXRe OR non-specific ECG abnormalities |  |

a United States Centers for Disease Control and Prevention.

b Cardiac magnetic resonance imaging.

c Creatine kinase myocardial band.

d Electrocardiogram.

e Chest X-ray.

# Author details

Dr Kevin M Slater1,2

Prof. Jim P Buttery1–4

Prof. Nigel W Crawford1–3

A/Prof. Daryl R Cheng1–4

1. SAEFVIC, Murdoch Children’s Research Institute, Parkville
2. Royal Children’s Hospital Melbourne, Parkville
3. Department of Paediatrics, University of Melbourne, Parkville
4. Centre for Health Analytics, Melbourne Children’s Campus, Parkville

Corresponding author

A/Prof. Daryl R Cheng

Address: SAEFVIC, Murdoch Children’s Research Institute, Parkville, Melbourne, Victoria

Phone: +61 3 9345 5522

Email: daryl.cheng@mcri.edu.au

# References

1. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148(3):e2021052478. doi: https://doi.org/10.1542/peds.2021-052478.
2. Marshall TR, Schrader S, Voss L, Buttery JP, Crawford NW, Cheng DR. A comparison of post-COVID vaccine myocarditis classification using the Brighton Collaboration criteria versus Centre for Disease Control criteria. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.2.
3. Sexson Tejtel SK, Munoz FM, Al-Ammouri I, Savorgnan F, Guggilla RK, Khuri-Bulos N et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40(10):1499–511. doi: https://doi.org/10.1016/j.vaccine.2021.11.074.
4. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977– 82. doi: https://doi.org/10.15585/mmwr.mm7027e2.

Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Protection Policy & Surveillance Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au

**Communicable Diseases Network Australia**

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Contacts**

CDI is produced by:

Health Protection Policy & Surveillance Division, Australian Government Department of Health and Aged Care,
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: www.health.gov.au/cdi

Email: cdi.editor@health.gov.au

**Submit an Article**

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: cdi.editor@health.gov.au.